StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

Research analysts at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued on Tuesday. The brokerage set a “sell” rating on the stock.

CEL-SCI Trading Down 5.6 %

Shares of CVM opened at $0.34 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.07 and a quick ratio of 1.09. The firm has a 50 day simple moving average of $0.44 and a 200-day simple moving average of $0.75. CEL-SCI has a 1-year low of $0.33 and a 1-year high of $2.50. The stock has a market cap of $26.14 million, a price-to-earnings ratio of -0.71 and a beta of 0.69.

Institutional Trading of CEL-SCI

Hedge funds have recently bought and sold shares of the company. Thoroughbred Financial Services LLC boosted its position in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after acquiring an additional 54,900 shares during the last quarter. Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI during the third quarter worth approximately $98,000. Finally, Geode Capital Management LLC boosted its position in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after acquiring an additional 53,879 shares during the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.